Pfanstiehl has announced it will be attending the AAPS PharmSci 360 conference.
Pfanstiehl will use this occasion to introduce its new High-Purity/Low-Endotoxin Low Metals L-Arginine, which meet United States Pharmacopoeia (USP), Europe Pharmacopoeia (EP), Japanese Pharmacopoeia (JP) and China Pharmacopoeia (ChP) requirements. It is manufactured in the US under strict current good manufacturing practice (cGMP) and International Conference on Harmonisation (ICH) Q7 compliant conditions.
To be held from 4-7 November in Washington DC, AAPS PharmSci 360 is one of the largest pharmaceutical sciences conferences, attracting hundreds of exhibitors showcasing some of the most innovative research in the field.
At the event, Pfanstiehl will also unveil additional newly launched products, all designed specifically for the biopharmaceutical and pharmaceutical markets. As part of Pfanstiehl’s continual commitment to producing the industry’s highest purity, lowest endotoxin and lowest metals for bioprocessing components, the new product specifications include ICH Q3D Elemental Impurity Data which is backed by extensive product characterisation. These new product specifications are also compliant with ChP.
Pfanstiehl invites you to join them at AAPS PharmSci to view its market-leading specifications firsthand and order your complimentary samples.
Please visit Pfanstiehl at Booth at Booth #2746.